Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q16647

UPID:
PTGIS_HUMAN

ALTERNATIVE NAMES:
Hydroperoxy icosatetraenoate dehydratase; Prostaglandin I2 synthase

ALTERNATIVE UPACC:
Q16647; Q3MII8; Q9HAX2; Q9HAX3; Q9HAX4

BACKGROUND:
Prostacyclin synthase, identified by the alternative name Hydroperoxy icosatetraenoate dehydratase, is integral to eicosanoid biosynthesis and metabolism. It converts prostaglandin H2 into prostacyclin, facilitating vasodilation and inhibiting platelet aggregation. Additionally, it acts on hydroperoxyeicosatetraenoates, especially targeting (15S)-HPETE, to exhibit dehydratase activity.

THERAPEUTIC SIGNIFICANCE:
The enzyme's involvement in essential hypertension highlights its potential as a target for therapeutic intervention. By modulating prostacyclin levels, it is possible to develop treatments for hypertension and related cardiovascular conditions, underscoring the therapeutic significance of Prostacyclin synthase.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.